ASX Penny Stocks: Helios Energy And 2 Others To Monitor
Name
Share Price
Market Cap
Financial Health Rating
GTN (ASX:GTN)
A$0.55
A$108.01M
★★★★★★
Regal Partners (ASX:RPL)
A$3.10
A$1.04B
★★★★★★
EZZ Life Science Holdings (ASX:EZZ)
A$1.715
A$80.9M
★★★★★★
IVE Group (ASX:IGL)
A$2.33
A$360.89M
★★★★★☆
Bisalloy Steel Group (ASX:BIS)
A$3.16
A$151.38M
★★★★★★
SHAPE Australia (ASX:SHA)
A$2.93
A$242.43M
★★★★★★
GR Engineering Services (ASX:GNG)
A$2.81
A$469.8M
★★★★★★
MotorCycle Holdings (ASX:MTO)
A$1.99
A$146.87M
★★★★★★
CTI Logistics (ASX:CLX)
A$1.755
A$136.91M
★★★★☆☆
Accent Group (ASX:AX1)
A$1.895
A$1.07B
★★★★☆☆
Click here to see the full list of 1,011 stocks from our ASX Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Helios Energy Limited is an onshore oil and gas exploration company operating in the United States, with a market cap of A$44.27 million.
Operations: The company generates revenue from its oil and gas exploration activities, amounting to A$0.14 million.
Market Cap: A$44.27M
Helios Energy Limited, with a market cap of A$44.27 million, is a pre-revenue company focused on oil and gas exploration in the U.S., generating minimal revenue of A$0.14 million. Recent strategic moves include the appointment of Mr. Edward J May as CFO and Mr. John Cathcart as Non-Executive Director, both bringing extensive industry experience which could strengthen financial oversight and strategic direction. Despite having more cash than total debt, Helios faces challenges with short-term liabilities exceeding assets and a volatile share price, but recent capital raised through convertible notes may provide some financial flexibility for future operations.
Navigate through the intricacies of Helios Energy with our comprehensive balance sheet health report here.
Explore historical data to track Helios Energy's performance over time in our past results report.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: K&S Corporation Limited operates in transportation and logistics, warehousing, and fuel distribution across Australia and New Zealand with a market cap of A$504.97 million.
Operations: The company's revenue is primarily derived from Australian Transport at A$553.12 million, Fuel at A$213.29 million, and New Zealand Transport at A$74.99 million.
Market Cap: A$504.97M
K&S Corporation Limited, with a market cap of A$504.97 million, shows mixed performance indicators typical of penny stocks. While its earnings have grown 25.5% annually over the past five years, recent results indicate a decline in sales and revenue compared to the previous year. The company's debt is well covered by operating cash flow, yet short-term assets do not cover long-term liabilities. Despite stable weekly volatility and no significant shareholder dilution recently, K&S's dividend yield is not fully supported by free cash flows, reflecting cautious optimism for potential investors in its logistics operations across Australia and New Zealand.
Unlock comprehensive insights into our analysis of K&S stock in this financial health report.
Review our historical performance report to gain insights into K&S' track record.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Pengana Capital Group (ASX:PCG) is a publicly owned investment manager with a market capitalization of A$76.79 million.
Operations: Pengana Capital Group does not report any specific revenue segments.
Market Cap: A$76.79M
Pengana Capital Group, with a market cap of A$76.79 million, has recently turned profitable, reporting half-year revenues of A$34.91 million and net income of A$3.5 million. The company has no debt, enhancing its financial stability and eliminating concerns over interest payments. Pengana's short-term assets significantly exceed both its short-term and long-term liabilities, indicating sound liquidity management. However, the return on equity remains low at 0.03%. The company announced a share buyback program to repurchase up to 10% of its shares by November 2025 and declared an ordinary dividend per share for the recent period ending December 2024.
Dive into the specifics of Pengana Capital Group here with our thorough balance sheet health report.
Assess Pengana Capital Group's future earnings estimates with our detailed growth reports.
Click through to start exploring the rest of the 1,008 ASX Penny Stocks now.
Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Jump on the AI train with fast growing tech companies forging a new era of innovation.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:HE8 ASX:KSC and ASX:PCG.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Here's Why We Think Coles Group (ASX:COL) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up. If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Coles Group (ASX:COL). While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Coles Group's Improving Profits Even with very modest growth rates, a company will usually do well if it improves earnings per share (EPS) year after year. So EPS growth can certainly encourage an investor to take note of a stock. Coles Group has grown its trailing twelve month EPS from AU$0.77 to AU$0.83, in the last year. That amounts to a small improvement of 8.4%. Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. EBIT margins for Coles Group remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 5.9% to AU$45b. That's progress. The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image. View our latest analysis for Coles Group The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Coles Group's future EPS 100% free. Are Coles Group Insiders Aligned With All Shareholders? We would not expect to see insiders owning a large percentage of a AU$27b company like Coles Group. But thanks to their investment in the company, it's pleasing to see that there are still incentives to align their actions with the shareholders. Indeed, they hold AU$53m worth of its stock. This considerable investment should help drive long-term value in the business. Despite being just 0.2% of the company, the value of that investment is enough to show insiders have plenty riding on the venture. It means a lot to see insiders invested in the business, but shareholders may be wondering if remuneration policies are in their best interest. Our quick analysis into CEO remuneration would seem to indicate they are. The median total compensation for CEOs of companies similar in size to Coles Group, with market caps over AU$12b, is around AU$6.4m. The Coles Group CEO received AU$4.7m in compensation for the year ending June 2024. That comes in below the average for similar sized companies and seems pretty reasonable. CEO compensation is hardly the most important aspect of a company to consider, but when it's reasonable, that gives a little more confidence that leadership are looking out for shareholder interests. It can also be a sign of good governance, more generally. Does Coles Group Deserve A Spot On Your Watchlist? One important encouraging feature of Coles Group is that it is growing profits. The fact that EPS is growing is a genuine positive for Coles Group, but the pleasant picture gets better than that. With a meaningful level of insider ownership, and reasonable CEO pay, a reasonable mind might conclude that this is one stock worth watching. Still, you should learn about the 2 warning signs we've spotted with Coles Group. While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in AU with promising growth potential and insider confidence. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
It Might Not Be A Great Idea To Buy Australian Foundation Investment Company Limited (ASX:AFI) For Its Next Dividend
Australian Foundation Investment Company Limited (ASX:AFI) stock is about to trade ex-dividend in 2 days. The ex-dividend date is usually set to be two business days before the record date, which is the cut-off date on which you must be present on the company's books as a shareholder in order to receive the dividend. It is important to be aware of the ex-dividend date because any trade on the stock needs to have been settled on or before the record date. This means that investors who purchase Australian Foundation Investment's shares on or after the 5th of August will not receive the dividend, which will be paid on the 28th of August. The company's next dividend payment will be AU$0.195 per share, on the back of last year when the company paid a total of AU$0.27 to shareholders. Last year's total dividend payments show that Australian Foundation Investment has a trailing yield of 3.5% on the current share price of AU$7.63. We love seeing companies pay a dividend, but it's also important to be sure that laying the golden eggs isn't going to kill our golden goose! So we need to check whether the dividend payments are covered, and if earnings are growing. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. Australian Foundation Investment distributed an unsustainably high 117% of its profit as dividends to shareholders last year. Without extenuating circumstances, we'd consider the dividend at risk of a cut. Generally, the higher a company's payout ratio, the more the dividend is at risk of being reduced. View our latest analysis for Australian Foundation Investment Click here to see how much of its profit Australian Foundation Investment paid out over the last 12 months. Have Earnings And Dividends Been Growing? Stocks in companies that generate sustainable earnings growth often make the best dividend prospects, as it is easier to lift the dividend when earnings are rising. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. This is why it's a relief to see Australian Foundation Investment earnings per share are up 2.7% per annum over the last five years. Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Australian Foundation Investment has delivered 1.4% dividend growth per year on average over the past 10 years. To Sum It Up Is Australian Foundation Investment an attractive dividend stock, or better left on the shelf? While we like that its earnings are growing somewhat, we're not enamored that it's paying out 117% of last year's earnings. Australian Foundation Investment doesn't appear to have a lot going for it, and we're not inclined to take a risk on owning it for the dividend. Although, if you're still interested in Australian Foundation Investment and want to know more, you'll find it very useful to know what risks this stock faces. In terms of investment risks, we've identified 1 warning sign with Australian Foundation Investment and understanding them should be part of your investment process. A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
an hour ago
- Yahoo
NeuroScientific Biopharmaceuticals (ASX:NSB) jumps 14% this week, though earnings growth is still tracking behind one-year shareholder returns
While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock market. When you buy and hold the right company, the returns can make a huge difference to both you and your family. For example, the NeuroScientific Biopharmaceuticals Limited (ASX:NSB) share price is up a whopping 576% in the last 1 year, a handsome return in a single year. Also pleasing for shareholders was the 410% gain in the last three months. The longer term returns have not been as good, with the stock price only 6.4% higher than it was three years ago. We love happy stories like this one. The company should be really proud of that performance! On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the last year NeuroScientific Biopharmaceuticals grew its earnings per share (EPS) by 54%. The share price gain of 576% certainly outpaced the EPS growth. So it's fair to assume the market has a higher opinion of the business than it a year ago. The fairly generous P/E ratio of 70.06 also points to this optimism. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). This free interactive report on NeuroScientific Biopharmaceuticals' earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further. A Different Perspective We're pleased to report that NeuroScientific Biopharmaceuticals shareholders have received a total shareholder return of 576% over one year. That's better than the annualised return of 1.2% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 4 warning signs we've spotted with NeuroScientific Biopharmaceuticals (including 2 which are potentially serious) . For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
